Stat 1 modification for antiviral defense
Stat 1 modification for antiviral defense
批准号:
7672133
负责人:
Michael J Holtzman
金额:
$38.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-09 至 2014-02-28
关键词:
AcuteAddressAntiviral AgentsAntiviral ResponseBehaviorBioinformaticsBiological AssayBioterrorismCandidate Disease GeneCell LineCell modelCellsChronic DiseaseClinicalCollaborationsComplementCowpox virusCysteineDataDependovirusDiagnosisDiagnosticDiseaseEffectivenessEncephalomyocarditis virusEngineeringEpidemicEpithelial CellsExhibitsGene ExpressionGene TransferGenesGenomeHistopathologyHumanImmune responseImmunohistochemistryIn VitroInfectionInflammationInfluenza A virusInterferon ActivationInterferon ReceptorInterferonsLaboratoriesMediatingModificationMolecularMolecular ProfilingMonitorMusMutationNatural ImmunityNatureOligonucleotide MicroarraysOutcomePatternPopulationPublic HealthRespiratory Tract InfectionsRouteSTAT1 geneSendai virusSignal PathwaySignal TransductionSignaling MoleculeSiteSmall Interfering RNASpecimenStructure of parenchyma of lungSystemTechnologyTestingTherapeuticTimeTissuesToxic effectTransgenesTransgenic MiceTransgenic OrganismsTreatment EfficacyVaccinesViralVirusVirus DiseasesVirus ReplicationWorkbasebiodefensecell typecellular engineeringcellular transductiondiagnostic accuracygene transfer vectorimprovedin vivomouse modelnovel diagnosticsnovel therapeuticsoverexpressionpathogenpromoterreceptor expressionrespiratoryresponsevectorvector control
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Viruses are among the most frequent causes of acute and chronic illness, and newly discovered viruses
continue to cause emergent diseases that resist established vaccines. Despite the scope of this problem, the
accuracy of diagnosis and efficacy of treatment for most viral infections, especially new types of infections, is
very limited in effectiveness. To address this issue, we have developed an alternative strategy that is aimed
at defining and then improving the antiviral host response. We focus particularly on respiratory infection
since this is a common route of natural infection and a likely route for delivery of bioterrorist threats. In that
regard, we have developed a system for primary-culture and infection of human airway epithelial cells that
exhibits high fidelity to behavior found in vivo. Our analysis of this epithelial cell model in concert with a
corresponding mouse model indicates that antiviral defense against respiratory viral infection depends
critically on interferon (IFN) activation of the Stall signaling molecule in airway epithelial cells. Based on
these findings, we proposed that improving Stall function in airway epithelial cells would enhance antiviral
defense. Accordingly, we engineered a modified Stall with strategic double-cysteine mutalions (designaled
Slal1-CC) that is hyperresponsive to endogenous interferon levels. Expression of Stall-CC should thereby
enhance interferon-signaling function and provide for better control of viral replication. Indeed, our
Preliminary Studies demonstrate that Stall-CC expression markedly decreases Ihe level of viral replication
both in vitro (using transduced cells) and in vivo (using transgenic or gene transfer technology). For example,
mice carrying the Stall-CC transgene or treated with a Stall-CC gene-transfer vector are fully protected
against otherwise lethal infections due to each of the three viruses studied thus far. Furthermore, we have
observed no toxicities of Stall-CC expression, in contrast to the situation for direct administralion or
overexpression of interferon itself. In this proposal, we aim to extend our approach to the study of emergent
pathogens with the capability for epidemic spread through the human population. In doing so, we aim to
establish infection capabilities and diagnostic signatures for these new viruses, a new therapeutic strategy
for these pathogens, and a better understanding of innate immunity to these agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining and Controlling Airway Disease
-
批准号:10352375
-
项目类别:
-
资助金额:$94.5万
-
财政年份:2019
-
负责人:Michael J Holtzman
-
依托单位:
Defining and Controlling Airway Disease
-
批准号:10579266
-
项目类别:
-
资助金额:$94.5万
-
财政年份:2019
-
负责人:Michael J Holtzman
-
依托单位:
Defining and Controlling Airway Disease
-
批准号:9889988
-
项目类别:
-
资助金额:$94.4万
-
财政年份:2019
-
负责人:Michael J Holtzman
-
依托单位:
TREM2 AND AIRWAY DISEASE
-
批准号:9335933
-
项目类别:
-
资助金额:$44.94万
-
财政年份:2016
-
负责人:Michael J Holtzman
-
依托单位:
IL-33 AND EXCESS MUCUS PRODUCTION
-
批准号:9223736
-
项目类别:
-
资助金额:$46.48万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
IL-33 AND EXCESS MUCUS PRODUCTION
-
批准号:8790768
-
项目类别:
-
资助金额:$46.92万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
Preclinical Development of an Anti-Mucus Drug
-
批准号:8748733
-
项目类别:
-
资助金额:$151.34万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
IL-33 AND EXCESS MUCUS PRODUCTION
-
批准号:8632665
-
项目类别:
-
资助金额:$48.19万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
INTERFERON SIGNAL ENHANCERS AS ANTIVIRAL THERAPEUTICS
-
批准号:8697863
-
项目类别:
-
资助金额:$44.09万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
Preclinical Development of an Anti-Mucus Drug
-
批准号:9317525
-
项目类别:
-
资助金额:$150.42万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
IL-33 AND EXCESS MUCUS PRODUCTION
-
批准号:8996714
-
项目类别:
-
资助金额:$47.06万
-
财政年份:2014
-
负责人:Michael J Holtzman
-
依托单位:
Target Validation and Assay Development for Anti-Mucus Therapy
-
批准号:8073309
-
项目类别:
-
资助金额:$45.6万
-
财政年份:2011
-
负责人:Michael J Holtzman
-
依托单位:
Stat 1 modification for antiviral defense
-
批准号:8234937
-
项目类别:
-
资助金额:$38.33万
-
财政年份:2011
-
负责人:Michael J Holtzman
-
依托单位:
Target Validation and Assay Development for Anti-Mucus Therapy
-
批准号:8262679
-
项目类别:
-
资助金额:$45.6万
-
财政年份:2011
-
负责人:Michael J Holtzman
-
依托单位:
New Immune Pathways for Epithelial Remodeling
-
批准号:8147488
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2010
-
负责人:Michael J Holtzman
-
依托单位:
Innate and Adaptive Immune Signaling in Asthma
-
批准号:7927711
-
项目类别:
-
资助金额:$197.63万
-
财政年份:2009
-
负责人:Michael J Holtzman
-
依托单位:
Innate and Adaptive Immune Signaling in Asthma
-
批准号:7918436
-
项目类别:
-
资助金额:$49.26万
-
财政年份:2009
-
负责人:Michael J Holtzman
-
依托单位:
Administrative
-
批准号:7392544
-
项目类别:
-
资助金额:$19.16万
-
财政年份:2007
-
负责人:Michael J Holtzman
-
依托单位:
Alveolar and Airway Mechanisms for COPD
-
批准号:7749011
-
项目类别:
-
资助金额:$280.3万
-
财政年份:2007
-
负责人:Michael J Holtzman
-
依托单位:
Alveolar and Airway Mechanisms for COPD
-
批准号:8004055
-
项目类别:
-
资助金额:$280.33万
-
财政年份:2007
-
负责人:Michael J Holtzman
-
依托单位:
海外基金